Randomized placebo-controlled trial comparing efficacy of nonablative fractional photothermolysis combined with topical calcipotriol for the treatment of keloid and hypertrophic scar

Authors

  • Marisa Pongprutthipan Chulalongkorn University and King Chulalongkorn Memorial Hospital.
  • Nattaporn Rojarayanont Chulalongkorn University and King Chulalongkorn Memorial Hospital.

Keywords:

Fractional erbium laser, hypertrophic scar, keloid, vitamin D3 analogue, topical calcipotriol

Abstract

Background : Nonablative fractional laser resurfacing has been shown to have size reduction effect on hypertrophic scar with minimal side effects; and antifibrotic effect of vitamin D in keloid fibroblasts has been reported in vitro. A combination of the two treatments should gain additional benefits from facilitation of wound healing, transdermal drug delivery and recurrence prevention.

Objectives : To evaluate the efficacy of nonablative fractional laser resurfacing combined with topical calcipotriol for the treatment of keloid and hypertrophic scar.

Methods : Subjects were treated with six fractional 1,550 nm Ytterbium/Erbium: fiber laser treatment weekly for entire lesion. Each lesion was randomly treated with topical calcipotriol or white petrolatum twice daily. Follow-up visits were done at week 6th and 12th. Clinical appraisal achieved by Patient and Observer Scar Assessment Scale (POSAS) and evaluator blinded photographic clinical assessment.

Results : Twelve subjects completed treatments in the study. Mean POSAS showed significant reduction (P <0.05) at week 6 but no statistical difference between groups was observed. Photographic clinical assessment had mild (1 - 25%) to moderate (26 - 50%) improvement in majority of the cases but there was no statistical difference between groups.

Conclusion : Nonablative fractional laser is an effective treatment for keloids and hypertrophic scars while the benefit of topical calcipotriol could not be demonstrated in the study.

Downloads

Download data is not yet available.

References

Shin JY, Yun SK, Roh SG, Lee NH, Yang KM. Efficacy of 2 Representative Topical Agents to Prevent Keloid Recurrence After Surgical Excision. J Oral Maxillofac Surg 2017;75: 401.

https://doi.org/10.1016/j.joms.2016.10.009

Fang QQ, Chen CY, Zhang MX, Huang CL, Wang XW, Xu JH, et al. The Effectiveness of Topical Anti-scarring Agents and a Novel Combined Process on Cutaneous Scar Management. Current Pharm Des 2016. Oct 25. [Epub ahead of print]. https://doi.org/10.2174/1381612822666161025144434

Zhang GY, Cheng T, Luan Q, Liao T, Nie CL, Zheng X, et al. Vitamin D: a novel therapeutic approach for keloid, an in vitro analysis. Br J Dermatol 2011;164:729-37.

https://doi.org/10.1111/j.1365-2133.2010.10130.x

Yu D, Shang Y, Luo S, Hao L. The TaqI gene polymorphisms of VDR and the circulating 1,25-dihydroxyvitamin D levels confer the risk for the keloid scarring in Chinese cohorts. Cell Physiol Biochem 2013;32:39-45. https://doi.org/10.1159/000350121

Niwa AB, Mello AP, Torezan LA, Osorio N. Fractional photothermolysis for the treatment of hypertrophic scars: clinical experience of eight cases. Dermatol Surg 2009;35:773-7.

https://doi.org/10.1111/j.1524-4725.2009.01127.x

Choi JE, Oh GN, Kim JY, Seo SH, Ahn HH, Kye YC. Ablative fractional laser treatment for hypertrophic scars: comparison between Er:YAG and CO2 fractional lasers. J Dermatolog Treat 2014;25:299-303.

https://doi.org/10.3109/09546634.2013.782090

Verhaeghe E, Ongenae K, Bostoen J, Lambert J. Nonablative fractional laser resurfacing for the treatment of hypertrophic scars: a randomized controlled trial. Dermatol Surg 2013;39:426-34.

https://doi.org/10.1111/dsu.12059

Amann PM, Marquardt Y, Steiner T, Holzle F, Skazik-Voogt C, Heise R, et al. Effects of non-ablative fractional erbium glass laser treatment on gene regulation in human three-dimensional skin models. Lasers Med Sci 2016;31:397-404. https://doi.org/10.1007/s10103-015-1863-x

de Sica RC, Rodrigues CJ, Maria DA, Cuce LC. Study of 1550nm Erbium Glass Laser Fractional non-ablative treatment of photoaging: Comparative clinical effects, histopathology, electron microscopy and immunohistochemistry. J Cosmet Laser Ther 2016:1-36. https://doi.org/10.3109/14764172.2015.1114645

Oni G, Brown SA, Kenkel JM. Can fractional lasers enhance transdermal absorption of topical lidocaine in an in vivo animal model? Lasers Surg Med 2012;44:168-74.

https://doi.org/10.1002/lsm.21130

Reinholz M, Poetschke J, Schwaiger H, Epple A, Ruzicka T, Gauglitz GG. The dermatology life quality index as a means to assess life quality in patients with different scar types. J Eur Acad Dermatol Venereol 2015;29: 2112-9. https://doi.org/10.1111/jdv.13135

Guy WM, Pattisapu P, Ongkasuwan J, Brissett AE. Creation of a head and neck Keloid quality of life questionnaire. Laryngoscope 2015;125:2672-6. https://doi.org/10.1002/lary.25309

Morkane C, Gregory JW, Watts P, Warner JT. Adrenal suppression following intralesional corticosteroids for periocular haemangiomas. Arch Dis Child 2011;96:587-9.

https://doi.org/10.1136/adc.2010.204859

Emir S, Gurlek Gokcebay D, Demirel F, Tunc B. Efficacy and safety of intralesional corticosteroid application for hemangiomas. Turk J Med Sci 2015;45:335-8. https://doi.org/10.3906/sag-1402-84

Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011;17:113-25..

https://doi.org/10.2119/molmed.2009.00153

Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-beta family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012;2:18-28.

Imaizumi R, Akasaka Y, Inomata N, Okada E, Ito K, Ishikawa Y, et al. Promoted activation of matrix metalloproteinase (MMP)-2 in keloid fibroblasts and increased expression of MMP-2 in collagen bundle regions: implications for mechanisms of keloid progression. Histopathology 2009;54:722-30.

https://doi.org/10.1111/j.1365-2559.2009.03287.x

Neely AN, Clendening CE, Gardner J, Greenhalgh DG, Warden GD. Gelatinase activity in keloids and hypertrophic scars. Wound Repair Regen 1999;7:166-71.

https://doi.org/10.1046/j.1524-475X.1999.00166.x

Uchida G, Yoshimura K, Kitano Y, Okazaki M, Harii K. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. Exp Dermatol 2003;12 Suppl 2:35-42.

https://doi.org/10.1034/j.1600-0625.12.s2.6.x

Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25- dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68:1500-10.

https://doi.org/10.1111/j.1523-1755.2005.00562.x

Halder SK, Osteen KG, Al-Hendy A. 1,25- dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod 2013; 89:150.

https://doi.org/10.1095/biolreprod.113.107714

Sahbaz A, Aynioglu O, Isik H, Gulle K, Akpolat Ferah M, Cicekler Sahbaz H. Cholecalciferol (vitamin D3) prevents postoperative adhesion formation by inactivating the nuclear factor kappa B pathway: a randomized experimental study. J Surg Res 2015;198:252-9. https://doi.org/10.1016/j.jss.2015.05.010

Yang L, Wang J, Fan Y, Chen S, Wang L, Ma J. Effect of 1,25(OH)(2)D(3) on rat peritoneal mesothelial cells treated with high glucose plus lipopolysaccharide. Cell Immunol 2011; 271:173-9.

https://doi.org/10.1016/j.cellimm.2011.06.017

Wahsh E, Abu-Elsaad N, El-Karef A, Ibrahim T. The vitamin D receptor agonist, calcipotriol, modulates fibrogenic pathways mitigating liver fibrosis in-vivo: An experimental study. Eur J Pharmacol 2016;789:362-9. https://doi.org/10.1016/j.ejphar.2016.07.052

Liang W, Lin Z, Zhang L, Qin X, Zhang Y, Sun L. Calcipotriol inhibits proliferation of human keratinocytes by downregulating STAT1 and STAT3 signaling. J Investig Med 2017;65: 376-81.

https://doi.org/10.1136/jim-2016-000176

van der Veer WM, Jacobs XE, Waardenburg IE, Ulrich MM, Niessen FB. Topical calcipotriol for preventive treatment of hypertrophic scars: a randomized, double-blind, placebocontrolled trial. Arch Dermatol 2009;145: https://doi.org/10.1001/archdermatol.2009.237:1269-75.

Waibel J, Wulkan AJ, Lupo M, Beer K, Anderson RR. Treatment of burn scars with the 1,550 nm nonablative fractional Erbium Laser. Lasers Surg Med 2012;44:441-6. https://doi.org/10.1002/lsm.22038

Reno F, Grazianetti P, Stella M, Magliacani G, Pezzuto C, Cannas M. Release and activation of matrix metalloproteinase-9 during in vitro mechanical compression in hypertrophic scars. Arch Dermatol 2002;138:475-8. https://doi.org/10.1001/archderm.138.4.475

Park JH, Chun JY, Lee JH. Laser-assisted topical corticosteroid delivery for the treatment of keloids. Lasers Med Sci 2017. Jan 26. doi: 10.1007/s10103-017-2154-5. https://doi.org/10.1007/s10103-017-2154-5

Hansen CM, Mathiasen IS, Binderup L. The antiproliferative and differentiation-inducing effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone. J Investig Dermatol Symp Proc 1996;1:44-8.

Manggau M, Kim DS, Ruwisch L, Vogler R, Korting HC, Schafer-Korting M, et al. 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001;117:1241-9 https://doi.org/10.1046/j.0022-202x.2001.01496.x

Downloads

Published

2023-08-23

How to Cite

1.
Pongprutthipan M, Rojarayanont N. Randomized placebo-controlled trial comparing efficacy of nonablative fractional photothermolysis combined with topical calcipotriol for the treatment of keloid and hypertrophic scar. Chula Med J [Internet]. 2023 Aug. 23 [cited 2024 Nov. 11];61(3). Available from: https://he05.tci-thaijo.org/index.php/CMJ/article/view/451